Effects of gefitinib (Iressa) on mammary cancers: Preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

Molecular Cancer Therapeutics

Volumn 7, Issue 4, 2008, Pages 972-979

  Lubet, Ronald A ^a   Szabo, Eva ^a   Christov, Konstantin ^b   Bode, Ann M ^c   Ericson, Marna E ^d   Steele, Vernon E ^a   Juliana, M Margaret ^e   Grubbs, Clinton J ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c University of Minnesota Hormel Institute   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; METHYLNITROSOUREA; VOROZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER REGRESSION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SKIN TOXICITY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOENZYME TECHNIQUES; MAMMARY NEOPLASMS, EXPERIMENTAL; METHYLNITROSOUREA; PHOSPHORYLATION; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TETRAHYDRONAPHTHALENES; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 42249091885     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2141     Document Type: Article

References (29)

1. Arteaga CT. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29:3-9.
2. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
4. Siziopikou K, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR targeted therapies. Breast 2007;16:104-7.
5. Hoadley KA, Weigman V, Fan C, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258. E Published July 31, 2007.
6. Baselga J, Albanell J, Ruiz A, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005;23:5323-33.
7. Von Minckwitz G, Jonat W, Fasching P, et al. A multicentre phase II study on gefitinib in taxane and anthracycline pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;89:165-72.
8. Polychronis A, Sinnett HD, Hadjiminas D, et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen receptor positive and epidermal growth factor receptor positive primary breast cancer: a double blind placebo controlled phase II randomized trial. Lancet Oncol 2005;6:383-91.
9. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606.
10. Huggins C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res 1965;25:1163-7.
11. Grubbs CJ, Peckham JC, Mc Donnough KD. Effect of ovarian hormones on the induction of 1-methyl-1-nitrosourea induced mammary cancer. Carcinogenesis 1983;4:495-7.
12. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990;62:244-78.
13. Chan MM, Lu X, Merchant FM, Inglehart JD, Miron PL. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis 2005;26:1343-53.
14. Gottardis M, Jordan C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020-4.
15. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994;15:2775-80.
16. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996;56:5566-70.
17. Lubet RA, Christov K, You M, et al. Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations. Mol Cancer Ther 2006;5:1073- 8.
18. Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007;13:5488-96.
19. Grubbs CJ, Lubet RA, Atigadda VR, et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers. Carcinogenesis 2006;27:1232-9.
20. Lubet RA, Gordon GB, Prough RA, et al. Modulation of methylnitrosourea- induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res 1998;58:921-6.
21. Christov K, Shilkaitis A, Green A, et al. Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole. Breast Cancer Res Treat 2000;60:117-28.
22. Wacnik PW, Baker CM, Herron MJ, et al. Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 2005;115:95-106.
23. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-43.
24. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the epidermal growth factor receptor. Nature 1984;311:483-5.
25. Sebastian S, Settleman, J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006;1766:120-39.
26. Lu C, Speers C, Zhang Y, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2003;95:1825-33.
27. Ciardiello F, Troiani T, Caputo F, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006;94:1604-9.
28. Suh N, Lamph WW, Glasebrook AI, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 2002;8:3270-5.
29. Smith IE, Walsh, G, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007;25:3816-22.